Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2014

Open Access 01-12-2014 | Original investigation

Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study

Authors: Maria-Agata Miselli, Edoardo Dalla Nora, Angelina Passaro, Franco Tomasi, Giovanni Zuliani

Published in: Cardiovascular Diabetology | Issue 1/2014

Login to get access

Abstract

Background

Cardiovascular disease (CVD) is the leading cause of death in type 2 diabetes mellitus (T2DM). American Diabetes Association standards of care set a series of targets recommended for the CVD prevention: blood pressure, LDL and HDL cholesterol (LDL-C and HDL-C), triglycerides and HbA1c goals. The aim of this study was to evaluate cardiovascular risk factors in a T2DM outpatient population in order to estimate their specific clinical value in predicting long-term overall mortality.

Methods

Our study population was co mposed of 1917 T2DM outpatients attending the hospital-based Diabetes Clinic of Ferrara for a mean follow-up period of 10 years; recorded information included personal, clinical and biochemical data, and pharmacological treatment.

Results

A Cox proportional hazard analysis was performed, pointing out as age (HR:1.08; IC95%: 1.06-1.11), sex (males: HR:1.97; IC95%: 1.26-3.07), mean triglycerides levels during follow-up (III vs I tertile: HR:1.87; IC95%: 1.12-3.12) and lipid-lowering treatment (HR:0.56; IC95%: 0.35-0.90) were significantly associated with all-cause mortality, independent of confounding factors such as mean values of LDL-C, HDL-C, HbA1c, blood pressure, BMI, fasting glucose, and antihypertensive and antidiabetic treatment.

Conclusions

This finding suggests that more attention should be given to the management of cardiovascular risk in type 2 diabetic patients with high triglycerides levels.
Literature
1.
go back to reference Kishore P, Kim SH, Crandall JP: Glycemic control and cardiovascular disease: what’s a doctor to do?. Curr Diab Rep. 2012, 12 (3): 255-264. 10.1007/s11892-012-0268-5.PubMedCentralCrossRefPubMed Kishore P, Kim SH, Crandall JP: Glycemic control and cardiovascular disease: what’s a doctor to do?. Curr Diab Rep. 2012, 12 (3): 255-264. 10.1007/s11892-012-0268-5.PubMedCentralCrossRefPubMed
2.
go back to reference Kreisberg RA: Diabetic dyslipidemia. Am J Cardiol. 1998, 82 (12A): 67U-73U. 10.1016/S0002-9149(98)00848-0. discussion 85U-86UCrossRefPubMed Kreisberg RA: Diabetic dyslipidemia. Am J Cardiol. 1998, 82 (12A): 67U-73U. 10.1016/S0002-9149(98)00848-0. discussion 85U-86UCrossRefPubMed
3.
go back to reference Fruchart JC: The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008, 102 (Suppl 10): 1K-34K. 10.1016/j.amjcard.2008.10.002.CrossRefPubMed Fruchart JC: The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008, 102 (Suppl 10): 1K-34K. 10.1016/j.amjcard.2008.10.002.CrossRefPubMed
4.
go back to reference Solano MP, Goldberg RB: Management of dyslipidemia in diabetes. Cardiol Rev. 2006, 14 (3): 125-135. 10.1097/01.crd.0000188034.76283.5e.CrossRefPubMed Solano MP, Goldberg RB: Management of dyslipidemia in diabetes. Cardiol Rev. 2006, 14 (3): 125-135. 10.1097/01.crd.0000188034.76283.5e.CrossRefPubMed
5.
go back to reference Tandon N, Ali MK, Narayan KM: Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes. Am J Cardiovasc Drugs. 2012, 12 (1): 7-22. 10.2165/11594650-000000000-00000.CrossRefPubMed Tandon N, Ali MK, Narayan KM: Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes. Am J Cardiovasc Drugs. 2012, 12 (1): 7-22. 10.2165/11594650-000000000-00000.CrossRefPubMed
6.
go back to reference Reiner Z: Managing the residual cardiovascular disease risk associated with HDL-Cholesterol and triglycerides in statin-treated patients: a clinical update. Nutr Metab Cardiovasc Dis. 2013, 23 (9): 799-807. 10.1016/j.numecd.2013.05.002.CrossRefPubMed Reiner Z: Managing the residual cardiovascular disease risk associated with HDL-Cholesterol and triglycerides in statin-treated patients: a clinical update. Nutr Metab Cardiovasc Dis. 2013, 23 (9): 799-807. 10.1016/j.numecd.2013.05.002.CrossRefPubMed
7.
go back to reference Nicholls SJ, Lundman P, Tardif JC: Diabetic dyslipidemia: extending the target beyond LDL cholesterol. Eur J Cardiovasc Prev Rehabil. 2010, 17 (Suppl 1): S20-4. 10.1097/01.hjr.0000368195.09485.17.CrossRefPubMed Nicholls SJ, Lundman P, Tardif JC: Diabetic dyslipidemia: extending the target beyond LDL cholesterol. Eur J Cardiovasc Prev Rehabil. 2010, 17 (Suppl 1): S20-4. 10.1097/01.hjr.0000368195.09485.17.CrossRefPubMed
8.
go back to reference Standards of medical care in diabetes--2013. Diabetes Care. 2013, 36 (Suppl 1): S11-66. 10.2337/dc13-S011. Standards of medical care in diabetes--2013. Diabetes Care. 2013, 36 (Suppl 1): S11-66. 10.2337/dc13-S011.
9.
go back to reference Standards of medical care in diabetes--2014. Diabetes Care. 2014, 37 (Suppl 1): S14-80. 10.2337/dc14-S014. Standards of medical care in diabetes--2014. Diabetes Care. 2014, 37 (Suppl 1): S14-80. 10.2337/dc14-S014.
10.
go back to reference Neeli H, Gadi R, Rader DJ: Managing diabetic dyslipidemia: beyond statin therapy. Curr Diab Rep. 2009, 9 (1): 11-17. 10.1007/s11892-009-0004-y.CrossRefPubMed Neeli H, Gadi R, Rader DJ: Managing diabetic dyslipidemia: beyond statin therapy. Curr Diab Rep. 2009, 9 (1): 11-17. 10.1007/s11892-009-0004-y.CrossRefPubMed
11.
go back to reference Bitzur R, Cohen H, Kamari Y, Shaish A, Harats D: Triglycerides and HDL cholesterol: stars or second leads in diabetes?. Diabetes Care. 2009, 32 (Suppl 2): S373-7. 10.2337/dc09-S343.PubMedCentralCrossRefPubMed Bitzur R, Cohen H, Kamari Y, Shaish A, Harats D: Triglycerides and HDL cholesterol: stars or second leads in diabetes?. Diabetes Care. 2009, 32 (Suppl 2): S373-7. 10.2337/dc09-S343.PubMedCentralCrossRefPubMed
12.
go back to reference Reiner Z, Catapano AL: ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2011, 32: 1769-1818. 10.1093/eurheartj/ehr158.CrossRefPubMed Reiner Z, Catapano AL: ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2011, 32: 1769-1818. 10.1093/eurheartj/ehr158.CrossRefPubMed
13.
go back to reference Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004, 44 (3): 720-732. 10.1016/j.jacc.2004.07.001.CrossRefPubMed Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004, 44 (3): 720-732. 10.1016/j.jacc.2004.07.001.CrossRefPubMed
14.
go back to reference Tenenbaum A, Fisman EZ, Motro M, Adler Y: Optimal management of combined dyslipidemia: what have we behind statins monotherapy?. Adv Cardiol. 2008, 45: 127-153. 10.1159/000115192.CrossRefPubMed Tenenbaum A, Fisman EZ, Motro M, Adler Y: Optimal management of combined dyslipidemia: what have we behind statins monotherapy?. Adv Cardiol. 2008, 45: 127-153. 10.1159/000115192.CrossRefPubMed
15.
go back to reference Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008, 358 (6): 580-591. 10.1056/NEJMoa0706245.CrossRefPubMed Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008, 358 (6): 580-591. 10.1056/NEJMoa0706245.CrossRefPubMed
16.
go back to reference Ryden L, Grant PJ: ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary. Diab Vasc Dis Res. 2014, 11 (3): 133-173. 10.1177/1479164114525548.CrossRefPubMed Ryden L, Grant PJ: ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary. Diab Vasc Dis Res. 2014, 11 (3): 133-173. 10.1177/1479164114525548.CrossRefPubMed
17.
go back to reference Perk J, De Backer G: European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J. 2012, 33: 1635-1701. 10.1093/eurheartj/ehs092.CrossRefPubMed Perk J, De Backer G: European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J. 2012, 33: 1635-1701. 10.1093/eurheartj/ehs092.CrossRefPubMed
18.
go back to reference Onat A, Sari I, Yazici M, Can G, Hergenc G, Avci GS: Plasma triglycerides, an independent predictor of cardiovascular disease in men: a prospective study based on a population with prevalent metabolic syndrome. Int J Cardiol. 2006, 108 (1): 89-95. 10.1016/j.ijcard.2005.06.056.CrossRefPubMed Onat A, Sari I, Yazici M, Can G, Hergenc G, Avci GS: Plasma triglycerides, an independent predictor of cardiovascular disease in men: a prospective study based on a population with prevalent metabolic syndrome. Int J Cardiol. 2006, 108 (1): 89-95. 10.1016/j.ijcard.2005.06.056.CrossRefPubMed
19.
go back to reference Cullen P: Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol. 2000, 86 (9): 943-949. 10.1016/S0002-9149(00)01127-9.CrossRefPubMed Cullen P: Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol. 2000, 86 (9): 943-949. 10.1016/S0002-9149(00)01127-9.CrossRefPubMed
20.
go back to reference Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996, 3 (2): 213-219. 10.1097/00043798-199604000-00014.CrossRefPubMed Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996, 3 (2): 213-219. 10.1097/00043798-199604000-00014.CrossRefPubMed
21.
go back to reference Toth PP, Simko RJ, Palli SR, Koselleck D, Quimbo RA, Cziraky MJ: The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2012, 11: 109-10.1186/1475-2840-11-109.PubMedCentralCrossRefPubMed Toth PP, Simko RJ, Palli SR, Koselleck D, Quimbo RA, Cziraky MJ: The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2012, 11: 109-10.1186/1475-2840-11-109.PubMedCentralCrossRefPubMed
22.
go back to reference Major Lipids, Apolipoproteins, and Risk of Vascular Disease. JAMA. 2009, 302 (18): 1993-2000. 10.1001/jama.2009.1619. Major Lipids, Apolipoproteins, and Risk of Vascular Disease. JAMA. 2009, 302 (18): 1993-2000. 10.1001/jama.2009.1619.
23.
go back to reference Keating GM, Croom KF: Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs. 2007, 67 (1): 121-153. 10.2165/00003495-200767010-00013.CrossRefPubMed Keating GM, Croom KF: Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs. 2007, 67 (1): 121-153. 10.2165/00003495-200767010-00013.CrossRefPubMed
24.
go back to reference Chapman MJ, Ginsberg HN: Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011, 32: 1345-61. 10.1093/eurheartj/ehr112.PubMedCentralCrossRefPubMed Chapman MJ, Ginsberg HN: Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011, 32: 1345-61. 10.1093/eurheartj/ehr112.PubMedCentralCrossRefPubMed
25.
go back to reference Colhoun H: After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?. Lancet. 2005, 366 (9500): 1829-1831. 10.1016/S0140-6736(05)67668-4.CrossRefPubMed Colhoun H: After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?. Lancet. 2005, 366 (9500): 1829-1831. 10.1016/S0140-6736(05)67668-4.CrossRefPubMed
26.
go back to reference Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, D'Emden M, Whiting M, Ehnholm C, Laakso M: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005, 366 (9500): 1849-1861. 10.1016/S0140-6736(05)67667-2.CrossRefPubMed Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, D'Emden M, Whiting M, Ehnholm C, Laakso M: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005, 366 (9500): 1849-1861. 10.1016/S0140-6736(05)67667-2.CrossRefPubMed
27.
go back to reference Tsimihodimos V, Mikhailidis DP, Elisaf M: Summarizing the FIELD study: lessons from a `negative’ trial. Expert Opin Pharmacother. 2013, 14 (18): 2601-2610. 10.1517/14656566.2013.850075.CrossRefPubMed Tsimihodimos V, Mikhailidis DP, Elisaf M: Summarizing the FIELD study: lessons from a `negative’ trial. Expert Opin Pharmacother. 2013, 14 (18): 2601-2610. 10.1517/14656566.2013.850075.CrossRefPubMed
28.
go back to reference Tenenbaum A, Fisman EZ: Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol. 2012, 11: 125-10.1186/1475-2840-11-125.PubMedCentralCrossRefPubMed Tenenbaum A, Fisman EZ: Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol. 2012, 11: 125-10.1186/1475-2840-11-125.PubMedCentralCrossRefPubMed
29.
go back to reference Boden WE, Probstfield JL: Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Eng J Med. 2011, 365: 2255-2267. 10.1056/NEJMoa1107579.CrossRef Boden WE, Probstfield JL: Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Eng J Med. 2011, 365: 2255-2267. 10.1056/NEJMoa1107579.CrossRef
30.
go back to reference Langsted A, Freiberg JJ, Tybjaerg-Hansen A, Schnohr P, Jensen GB, Nordestgaard BG: Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. J Intern Med. 2011, 270 (1): 65-75. 10.1111/j.1365-2796.2010.02333.x.CrossRefPubMed Langsted A, Freiberg JJ, Tybjaerg-Hansen A, Schnohr P, Jensen GB, Nordestgaard BG: Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. J Intern Med. 2011, 270 (1): 65-75. 10.1111/j.1365-2796.2010.02333.x.CrossRefPubMed
31.
go back to reference Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004, 364 (9435): 685-696. 10.1016/S0140-6736(04)16895-5.CrossRefPubMed Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004, 364 (9435): 685-696. 10.1016/S0140-6736(04)16895-5.CrossRefPubMed
32.
go back to reference Nesto RW: Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs. 2005, 5 (6): 379-387. 10.2165/00129784-200505060-00005.CrossRefPubMed Nesto RW: Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs. 2005, 5 (6): 379-387. 10.2165/00129784-200505060-00005.CrossRefPubMed
33.
go back to reference McFarlane SI, Muniyappa R, Francisco R, Sowers JR: Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab. 2002, 87 (4): 1451-1458. 10.1210/jcem.87.4.8412.CrossRefPubMed McFarlane SI, Muniyappa R, Francisco R, Sowers JR: Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab. 2002, 87 (4): 1451-1458. 10.1210/jcem.87.4.8412.CrossRefPubMed
34.
go back to reference Wang CY, Liu PY, Liao JK: Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008, 14 (1): 37-44. 10.1016/j.molmed.2007.11.004.PubMedCentralCrossRefPubMed Wang CY, Liu PY, Liao JK: Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008, 14 (1): 37-44. 10.1016/j.molmed.2007.11.004.PubMedCentralCrossRefPubMed
35.
go back to reference Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. 1995. Atheroscler Suppl. 2004, 5 (3): 91-97. 10.1016/j.atherosclerosissup.2004.08.029.CrossRefPubMed Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. 1995. Atheroscler Suppl. 2004, 5 (3): 91-97. 10.1016/j.atherosclerosissup.2004.08.029.CrossRefPubMed
36.
go back to reference Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996, 335 (14): 1001-1009. 10.1056/NEJM199610033351401.CrossRefPubMed Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996, 335 (14): 1001-1009. 10.1056/NEJM199610033351401.CrossRefPubMed
37.
go back to reference Papanas N, Maltezos E, Mikhailidis DP: Metformin: diamonds are forever. Expert Opin Pharmacother. 2009, 10 (15): 2395-2397. 10.1517/14656560903176453.CrossRefPubMed Papanas N, Maltezos E, Mikhailidis DP: Metformin: diamonds are forever. Expert Opin Pharmacother. 2009, 10 (15): 2395-2397. 10.1517/14656560903176453.CrossRefPubMed
38.
go back to reference Krentz AJ, Bailey CJ: Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005, 65 (3): 385-411. 10.2165/00003495-200565030-00005.CrossRefPubMed Krentz AJ, Bailey CJ: Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005, 65 (3): 385-411. 10.2165/00003495-200565030-00005.CrossRefPubMed
39.
go back to reference Scarpello JH, Howlett HC: Metformin therapy and clinical uses. Diab Vasc Dis Res. 2008, 5 (3): 157-167. 10.3132/dvdr.2008.027.CrossRefPubMed Scarpello JH, Howlett HC: Metformin therapy and clinical uses. Diab Vasc Dis Res. 2008, 5 (3): 157-167. 10.3132/dvdr.2008.027.CrossRefPubMed
40.
go back to reference Holman R: Metformin as first choice in oral diabetes treatment: the UKPDS experience. Journ Annu Diabetol Hotel Dieu. 2007, x: 13-20. Holman R: Metformin as first choice in oral diabetes treatment: the UKPDS experience. Journ Annu Diabetol Hotel Dieu. 2007, x: 13-20.
41.
go back to reference Scarpello JH: Improving survival with metformin: the evidence base today. Diabetes Metab. 2003, 29 (4 Pt 2): 6S36-43.PubMed Scarpello JH: Improving survival with metformin: the evidence base today. Diabetes Metab. 2003, 29 (4 Pt 2): 6S36-43.PubMed
Metadata
Title
Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study
Authors
Maria-Agata Miselli
Edoardo Dalla Nora
Angelina Passaro
Franco Tomasi
Giovanni Zuliani
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2014
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-014-0135-6

Other articles of this Issue 1/2014

Cardiovascular Diabetology 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.